Reported Earnings • Nov 29
First quarter 2026 earnings released: kr0.002 loss per share (vs kr0.096 loss in 1Q 2025) First quarter 2026 results: kr0.002 loss per share (improved from kr0.096 loss in 1Q 2025). Revenue: kr6.00m (up kr5.85m from 1Q 2025). Net loss: kr37.1k (loss narrowed 98% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 31
Full year 2025 earnings released: kr0.32 loss per share (vs kr0.037 loss in FY 2024) Full year 2025 results: kr0.32 loss per share (further deteriorated from kr0.037 loss in FY 2024). Revenue: kr3.36m (down 85% from FY 2024). Net loss: kr5.88m (loss widened kr5.31m from FY 2024). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings. Annuncio • Jul 29
ODI Pharma AB (publ) to Report Fiscal Year 2025 Results on Aug 28, 2025 ODI Pharma AB (publ) announced that they will report fiscal year 2025 results on Aug 28, 2025 New Risk • Jul 27
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr6.7m free cash flow). Share price has been highly volatile over the past 3 months (41% average weekly change). Market cap is less than US$10m (kr27.3m market cap, or US$2.87m). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Revenue is less than US$5m (kr11m revenue, or US$1.1m). New Risk • May 30
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr6.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr6.7m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Revenue is less than US$1m (kr7.5m revenue, or US$786k). Market cap is less than US$10m (kr36.3m market cap, or US$3.78m). Reported Earnings • Feb 28
Second quarter 2025 earnings released: kr0.17 loss per share (vs kr0.062 profit in 2Q 2024) Second quarter 2025 results: kr0.17 loss per share (down from kr0.062 profit in 2Q 2024). Revenue: kr74.0k (up kr72.9k from 2Q 2024). Net loss: kr2.56m (down 371% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Annuncio • Jan 29
ODI Pharma AB (publ) to Report Q2, 2025 Results on Feb 27, 2025 ODI Pharma AB (publ) announced that they will report Q2, 2025 results on Feb 27, 2025 Annuncio • Dec 30
ODI Pharma AB (publ) Appoints Jan-Mark Edewaard as Board Member ODI Pharma AB (publ) announced that at the AGM held on December 30, 2024, approved the appointment of Jan-Mark Edewaard as board member. Annuncio • Dec 12
ODI Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 2.238009 million. ODI Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 2.238009 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 695,034
Price\Range: SEK 3.22
Transaction Features: Rights Offering New Risk • Dec 04
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Market cap is less than US$10m (kr48.7m market cap, or US$4.46m). Minor Risk Revenue is less than US$5m (kr22m revenue, or US$2.0m). Reported Earnings • Nov 24
First quarter 2025 earnings released: kr0.096 loss per share (vs kr0.095 loss in 1Q 2024) First quarter 2025 results: kr0.096 loss per share (further deteriorated from kr0.095 loss in 1Q 2024). Revenue: kr251.3k (down 52% from 1Q 2024). Net loss: kr1.47m (loss widened 1.8% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Annuncio • Oct 30
ODI Pharma AB (publ) to Report Q1, 2025 Results on Nov 22, 2024 ODI Pharma AB (publ) announced that they will report Q1, 2025 results on Nov 22, 2024 Reported Earnings • Aug 30
Full year 2024 earnings released: EPS: kr0.023 (vs kr0.45 loss in FY 2023) Full year 2024 results: EPS: kr0.023 (up from kr0.45 loss in FY 2023). Revenue: kr25.4m (up kr25.3m from FY 2023). Net income: kr356.0k (up kr7.26m from FY 2023). Profit margin: 1.4% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Annuncio • Jul 31
ODI Pharma AB (publ) to Report Fiscal Year 2024 Results on Aug 29, 2024 ODI Pharma AB (publ) announced that they will report fiscal year 2024 results on Aug 29, 2024 Reported Earnings • Jun 04
Third quarter 2024 earnings released: EPS: kr0.085 (vs kr0.062 loss in 3Q 2023) Third quarter 2024 results: EPS: kr0.085 (up from kr0.062 loss in 3Q 2023). Revenue: kr13.9m (up kr13.9m from 3Q 2023). Net income: kr1.30m (up kr2.24m from 3Q 2023). Profit margin: 9.3% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings. Annuncio • May 03
ODI Pharma AB Provides Sales Guidance for the Third Quarter of the Year 2024 ODI Pharma AB provided sales guidance for the third quarter of the year 2024. For the quarter, the company's sales are expected to exceed SEK 13.5 million. This increase in revenue largely results from their successful partnership with Synoptis Pharma, which has led to several product shipments. Annuncio • May 01
ODI Pharma AB (publ) to Report Q3, 2024 Results on May 30, 2024 ODI Pharma AB (publ) announced that they will report Q3, 2024 results on May 30, 2024 Reported Earnings • Feb 25
Second quarter 2024 earnings released: EPS: kr0.062 (vs kr0.11 loss in 2Q 2023) Second quarter 2024 results: EPS: kr0.062 (up from kr0.11 loss in 2Q 2023). Revenue: kr2.95m (up kr2.88m from 2Q 2023). Net income: kr946.5k (up kr2.68m from 2Q 2023). Profit margin: 32% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Annuncio • Jan 24
ODI Pharma AB (publ) to Report Q2, 2024 Results on Feb 22, 2024 ODI Pharma AB (publ) announced that they will report Q2, 2024 results on Feb 22, 2024 Reported Earnings • Nov 26
First quarter 2024 earnings released: kr0.095 loss per share (vs kr0.10 loss in 1Q 2023) First quarter 2024 results: kr0.095 loss per share (improved from kr0.10 loss in 1Q 2023). Revenue: kr534.3k (up kr506.3k from 1Q 2023). Net loss: kr1.44m (loss narrowed 10.0% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Annuncio • Nov 24
ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Nov 24, 2023 ODI Pharma AB (publ) announced that they will report fiscal year 2023 results on Nov 24, 2023 Annuncio • Nov 14
ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023 ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023, at 10:30 Central European Standard Time. Location: In the office of the company at Östermalmstorg 1, 114 42 Stockholm Stockholm Sweden Agenda: To consider the presentation of the annual report and auditor's report; to consider the adoption of the income statement and the balance sheet; to consider allocation of the company's result according to the adopted balance sheet; to consider discharge from liability for board members and the managing director; to consider determination of the number of members in the board of directors, alternate members, and the number of auditors and alternate auditors; to consider the election of the Board of Directors and accounting firm or auditors; and to consider other matters. Annuncio • Oct 25
ODI Pharma AB (publ) to Report Q1, 2024 Results on Nov 23, 2023 ODI Pharma AB (publ) announced that they will report Q1, 2024 results on Nov 23, 2023 Reported Earnings • Aug 27
Full year 2023 earnings released: kr0.41 loss per share (vs kr0.48 loss in FY 2022) Full year 2023 results: kr0.41 loss per share (improved from kr0.48 loss in FY 2022). Net loss: kr6.16m (loss narrowed 15% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Annuncio • Jul 26
ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Aug 24, 2023 ODI Pharma AB (publ) announced that they will report fiscal year 2023 results on Aug 24, 2023 Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annuncio • Jan 15
ODI Pharma AB Proceeds with Its Plans and Launches Project Skin ODI Pharma AB announced that the Board of Directors has decided to expand ODI's current business with specialized, highly CBD-infused skin care products. The Board of Directors sees Project Skin as a great platform to further build ODI Pharma's reputation and brand awareness. The products will be launched EU wide, with initial focus on a few markets, including Sweden. The Company will keep the market informed about the next step in the process. Annuncio • Nov 12
ODI Pharma AB (publ), Annual General Meeting, Dec 14, 2020 ODI Pharma AB (publ), Annual General Meeting, Dec 14, 2020, at 10:00 Central European Standard Time. Location: Engelbrektsgatan 9-11 in Stockholm Stockholm Sweden Agenda: To consider Election of one or two persons to attest the minutes, where applicable; To consider Presentation of the annual report and auditor's report; To consider adoption of the income statement and the balance sheet and; To consider allocation of the company's profit or loss according to the adopted balance sheet; To consider discharge from liability for board members and the managing director; To consider amend the Articles of Association. Annuncio • Nov 03
Odi Pharma AB and Aphria Inc. Execute Supply Agreement ODI Pharma AB (publ) announced it has streamlined its supply chain and executed a Supply Agreement with Aphria Inc.'s wholly-owned German subsidiary, CC Pharma GmbH. The management team of ODI believes the Supply Agreement will contribute to efficiencies of ODI's operations going forward. The Supply Agreement grants ODI the exclusive right to sell a defined set of co-branded products in Poland. These products will be co-branded and sold under the ODI and Aphria brand names; ·The Supply Agreement has a term of five years and provides for an annual minimum of 1,200 kg of medical cannabis product, for a total of 6,000 kg of medical cannabis during the term of the agreement; and CC Pharma will support ODI in securing regulatory approval for import and sale of the co-branded products in Poland. Is New 90 Day High Low • Oct 29
New 90-day low: kr4.61 The company is down 5.0% from its price of kr4.83 on 29 July 2020. The Swedish market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period. 
